Abstract:Highlights • Preparing pharmaceutical salts of tetrahydropalmatine-sulfamic acid (THP-SA). • Improving solubility of THP by forming THP-SA introducing sulfamic acid. • THP and SA form pharmaceutical salts with the superhelical structure. • The improved solubility of THP may be due to the supramolecular helical structure. In order to improve the solubility of tetrahydropalmatine (THP), based on the summary of the relationship between cocrystal/salt synthesis and conformation of the protoberberine type compounds, we hypothesized that by introducing sulfamic acid (SA) with the sulfonic acid group may form cocrystal with THP and improve the solubility of THP. An unreported pharmaceutical salt (C 21 H 26 NO 4 ·SO 3 NH 2 , THP-SA) with supramolecular helical structure of THP and SA was designed and synthesized, and its structural characterization and properties were investigated. Structural analysis showed that the pharmaceutical salt with supramolecular helical structure were formed by introducing SA with THP. In THP-SA pharmaceutical salts, the protons of hydroxyl groups on the introduced SA were transferred to the nitrogen atom of the THP via charge-assisted hydrogen bonding (+) CAHBs (N + -H···O − ) to form a stable crystal structure. Meanwhile, the S atom in the sulfamic acid forms an angle of 116.16° with the O atom, so that the two THP and the two SA are connected sequentially by the 116.16° angle formed between the S atom and the O atom under the action of C–H⋯O hydrogen bond to form the R 3 4 (17) supramolecular synthons. And THP and SA are alternately connected by C–H⋯O hydrogen bonds, forming a left-handed helical chain and a right-handed helical chain along the a-axis, and the left-handed helical chains and right-handed helical chains are connected by C–H⋯O hydrogen bonds formed between the O atoms in SA and the C atoms in THP to form a 3D supramolecular double helix structure. As expected, solubility studies showed that the solubility of THP-SA was significantly improved compared to that of THP. The reason may be that the introduction of SA makes THP and SA form a helical steric structure, and the intermolecular arrangement tightness is reduced, which is conducive to the entry of water molecules. And THP and SA depend on CAHBs to form pharmaceutical salts, which changes THP from neutral to ionized, resulting in increased solubility of THP. This work implies that THP can improve its physicochemical properties by introducing special coformers to form pharmaceutical salts with supramolecular helical structure, which provides a theoretical basis for the subsequent improvement of the physicochemical properties of the protoberberine type compounds. Graphical abstract Download : Download high-res image (329KB) Download : Download full-size image

A series of stable, metastable and unstable salts of Imatinib with improved solubility

Molecular Salts of Drug Famotidine with Isomeric Dihydroxybenzoic Acids

Solid amorphous formulations for enhancing solubility and inhibiting Erlotinib crystallization during gastric-to-intestinal transfer

Effects of Formulation Variables on the Particle Size and Drug Encapsulation of Imatinib-Loaded Solid Lipid Nanoparticles

A New Strategy to Design Isostructural Salts: the Case of the Antitumor Drug Dimethylaminomicheliolide

Stable Cocrystals and Salts of the Antineoplastic Drug Apatinib with Improved Solubility in Aqueous Solution

Metformin-NSAIDs Molecular Salts: A Path towards Enhanced Oral Bioavailability and Stability

Improving the Solubility, Stability, and Bioavailability of Albendazole through Synthetic Salts

Optimization of precipitation conditions for producing physically stable amorphous solids using pair distribution function and reduced crystallization temperature

ENHANCED SOLUBILITY AND DISSOLUTION BY SURFACE-MODIFIED SOLID DISPERSION OF ALECTINIB HYDROCHLORIDE

Preparation, characterization, and crystal structures of novel sophocarpine salts with improvements on stability and solubility

Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid–base neutralization approach

Kinetics of crystal transformation of imatinib mesylate during formulation process: Selection of dry granulation in pharmaceutical process

New Case of Pharmaceutical Solid-State Forms: Several Novel Solvates/Polymorphs of Nilotinib and Their Phase Transformation Controls

The use of inorganic salts to improve the dissolution characteristics of tablets containing Soluplus®-based solid dispersions

Ciprofloxacin salts of benzene mono/di-carboxylate: Crystal structures and the improvement of solubility

Improving the solubility of tetrahydropalmatine by introducing sulfonic acid by forming pharmaceutical salts of tetrahydropalmatine with supramolecular helical structure via CAHBs

“Drug–Coformer–Drug” Multicomponent Crystals to Simultaneously Improve the Solubility of Two Insoluble Combined Drugs by Introduction of a Soluble Coformer

The enhanced pH-dependent solubility behavior of three novel lamotrigine-acid salts

Preparation, characterization, and stability enhancement of metoprolol pharmaceutical multicomponent crystals

A novel solubilization technique for poorly soluble drugs through the integration of nanocrystal and cocrystal technologies